Beacon Therapeutics
Generated by Meeveem AI
"Restoring sight through pioneering gene therapy for rare and prevalent retinal diseases"
Alachua, FL
•51 - 250 Employees
•Biotechnology
About Beacon Therapeutics
Beacon Therapeutics develops gene therapies to save and restore vision for people with blinding ocular diseases. Using AAV gene therapy, the company delivers functional genes to retinal cells, treating X-Linked Retinitis Pigmentosa, geographic atrophy, and cone rod dystrophy. Their lead therapy, laru-zova, is progressing through Phase 2 and Phase 3 clinical trials. The company addresses the need for treatments in rare and prevalent retinal diseases causing progressive vision loss. Gene therapy offers durable improvements in retinal function and quality of life for patients with limited options. Patients facing inherited and age related retinal conditions gain hope for preserved and restored sight.
90
Team Members
2023
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where gene therapy transforms the lives of people with retinal diseases, preventing blindness and restoring vision to create lasting impact for patients and their families.
Our Mission
At Beacon Therapeutics, our mission is to save and restore sight for people living with rare and prevalent ocular diseases through pioneering gene therapy.